Performance of Clinical and Biochemical Parameters in Identifying Renal Histopathology and Predictors of One-Year Renal Outcome in Lupus Nephritis—A Single Centre Study from India

Objectives: To assess the performance of clinical and biochemical parameters in identifying renal histopathology. To assess the performance of a combination of demographic, clinical, serological and histopathological parameters in determining renal response at one year. Methods: Data of biopsy-proven (ISN/RPS—2003 criteria) Lupus Nephritis (LN) were extracted from the institute database. Demographic, clinical and biochemical parameters at the time of biopsy were noted, and their associations with histopathological class, activity and chronicity scores were evaluated. Follow-up data at one year were collected. Complete, partial or no response (CR, PR, NR) for renal outcomes at one year and the predictors of NR were assessed. Results: Out of the 333 renal biopsies, 240 (71.8%) were Class III/IV. More patients with Class III/IV LN had hypertension (52.1%) and low eGFR (p < 0.001). Among Class III/IV, AS correlated weakly with UPCR (r = 0.31, p < 0.01), eGFR (r = −0.172; p < 0.01) and CS with eGFR (r = −0.212; p < 0.01). The presence of either hypertension, UPCR > 0.5 g/day, active urinary sediments or serum creatinine >1.3 g/dL had a sensitivity of >96% and specificity of <9% in detecting proliferative LN, crescents, interstitial inflammation and chronicity. NR was higher in males (aOR:3.9, 95% CI:1.4–11.0, p < 0.001), those with abnormal baseline creatinine (aOR: 1.9, 95% CI: 1.1–3.2, p < 0.001), higher renal SLEDAI (p < 0.05), higher AS, CS (p < 0.001) and interstitial inflammation (p < 0.005). In the binary logistic regression, the combination of male sex, baseline creatinine, UPCR and CS performed best in predicting NR (AUC: 0.762; 95% CI: 0.684–0.840, p < 0.001). Conclusions: Clinical and biochemical parameters alone have a poor specificity in identifying renal histopathology. A combination of demographic, clinical and histopathology parameters can better predict renal outcomes at one year.

[1]  G. Cattoretti,et al.  Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV , 2022, Annals of the Rheumatic Diseases.

[2]  J. Kothari,et al.  Long-term outcome and predictors of long-term outcome in patients with lupus nephritis managed at a tertiary hospital in Mumbai , 2022, Lupus.

[3]  E. Taylor,et al.  Antihypertensive effects of immunosuppressive therapy in autoimmune disease , 2022, Journal of Human Hypertension.

[4]  S. Quaglini,et al.  Beyond ISN/RPS Lupus Nephritis Classification: Adding Chronicity Index to Clinical Variables Predicts Kidney Survival , 2021, Kidney360.

[5]  L. Trupin,et al.  High Disease Severity Among Asian Patients in a US Multiethnic Cohort of Individuals With Systemic Lupus Erythematosus , 2020, Arthritis care & research.

[6]  S. Quaglini,et al.  Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[7]  E. Frangou,et al.  2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[8]  Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.

[9]  T. Nishino,et al.  Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study , 2019, Lupus.

[10]  B. Rovin,et al.  Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis , 2019, Lupus Science & Medicine.

[11]  Agnes B. Fogo,et al.  Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.

[12]  V. Negi,et al.  Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study , 2018, Rheumatology International.

[13]  C. Putterman,et al.  Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. , 2018, Seminars in arthritis and rheumatism.

[14]  B. Rovin,et al.  Update on Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[15]  Vladimir Tesar,et al.  Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Ron Wolterbeek,et al.  Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[17]  K. Gupta,et al.  Effect of Thrombotic Microangiopathy on Clinical Outcomes in Indian Patients With Lupus Nephritis , 2017, Kidney international reports.

[18]  T. J. Kim,et al.  Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis , 2017, Lupus.

[19]  B. Rovin,et al.  Current and Emerging Therapies for Lupus Nephritis. , 2016, Journal of the American Society of Nephrology : JASN.

[20]  W. van Biesen,et al.  Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications , 2016, American Journal of Nephrology.

[21]  M. Clark,et al.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. , 2015, Seminars in nephrology.

[22]  J. Lane,et al.  Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance , 2015, Pediatric Rheumatology.

[23]  B. Rovin,et al.  Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort , 2015, Arthritis & rheumatology.

[24]  A. Ahmadi,et al.  Clinicopathological correlations in lupus nephritis; a single center experience , 2014, Journal of nephropathology.

[25]  D. Gladman,et al.  Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment , 2014, The Journal of Rheumatology.

[26]  J. Ahearn,et al.  Biomarkers in systemic lupus erythematosus: challenges and prospects for the future , 2013, Therapeutic advances in musculoskeletal disease.

[27]  H. Yamanaka,et al.  Frequency of Class III and IV Nephritis in Systemic Lupus Erythematosus Without Clinical Renal Involvement: An Analysis of Predictive Measures , 2012, The Journal of Rheumatology.

[28]  T. Cheng,et al.  Age- and gender-related long-term renal outcome in patients with lupus nephritis , 2011, Lupus.

[29]  T. Utset,et al.  Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring , 2011, Arthritis care & research.

[30]  M. Mok,et al.  Do Asian patients have worse lupus? , 2010, Lupus.

[31]  E. Bonfá,et al.  Male gender results in more severe lupus nephritis , 2010, Rheumatology International.

[32]  I. Bruce,et al.  Numerical scoring for the BILAG-2004 index , 2010, Rheumatology.

[33]  Su-xia Wang,et al.  Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. , 2009, Kidney international.

[34]  D. Isenberg,et al.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[35]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[36]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[37]  Joni K. Evans,et al.  Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. , 2001, Kidney international.

[38]  L R Muenz,et al.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. , 1984, Kidney international.

[39]  V. Jha,et al.  Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. , 2016, Kidney international.

[40]  J. Ioannidis,et al.  Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. , 2000, Kidney international.